Pluristem Therapeutics, Inc. (NASDAQ: PSTI) is a regenerative biotherapeutics corporation focused on commercializing non-personalized (allogeneic) stem cell therapy products for the treatment of severe degenerative, malignant, and autoimmune disorders. The company is dedicated to developing a platform designed to create stem cell-based therapeutic products that can treat severe blood, cardiovascular, autoimmune, and other disorders.
The company is currently developing the PluriX™ 3D Bioreactor System, which is designed to create an artificial physiological environment where mesenchymal stem cells can expand in three dimensions and reproduce without the use of exogenous biologics or pharmacological products. This new method is superior to the traditional method of MSC expansion that uses standard, two-dimensional cell culture techniques in conjunction with fetal bovine serum, growth factors, and leukemia inhibitory factor.
Pluristem’s products are obtained from mesenchymal stromal cells found in the placenta—not from controversial embryonic stem cells—and are stored in a readily available state for patient use. The company anticipates that this new technology has the potential to partake of the approximately $30-billion therapeutic and regenerative cellular industries.
Let us hear your thoughts: Pluristem Therapeutics, Inc. Message Board